Bank Of New York Mellon Corp Aadi Bioscience, Inc. Transaction History

Bank Of New York Mellon Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 25, 2024	SELL	$1.59 - $2.44 $9,794 - $15,030	-6,160 Reduced 12.32%	43,858 $103 Million
Q4 2023 Jan 29, 2024	BUY	$1.97 - $5.41 $1,605 - $4,409	815 Added 1.66%	50,018 $101 Million
Q3 2023 Oct 24, 2023	BUY	$4.84 - $7.13 $2,400 - $3,536	496 Added 1.02%	49,203 $238 Million
Q2 2023 Aug 03, 2023	BUY	$6.84 - $8.56 $19,234 - $24,070	2,812 Added 6.13%	48,707 $333 Million
Q1 2023 May 09, 2023	BUY	$6.85 - $13.0 $314,380 - $596,635	45,895 New	45,895 $332 Million
Q4 2022 Feb 14, 2023	BUY	$11.99 - $14.5 $556,899 - $673,481	46,447 New	46,447 $595,000
Q3 2022 Nov 14, 2022	BUY	$12.03 - $14.22 $45,593 - $53,893	3,790 Added 9.03%	45,775 $647,000
Q2 2022 Aug 15, 2022	BUY	$11.57 - $17.92 $354,956 - $549,767	30,679 Added 271.35%	41,985 $517,000
Q4 2021 Feb 11, 2022	BUY	$19.32 - $29.02 $218,431 - $328,100	11,306 New	11,306 $273,000

12.6M

23.8K

Ticker AADI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 21,016,800
Market Cap $78.4M
Description
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.